<DOC>
	<DOCNO>NCT01904318</DOCNO>
	<brief_summary>A dose block-randomized , double-blinded , placebo-controlled , single dose , dose-escalation clinical phase I study evaluate safety , pharmacokinetics food effect IDP-73152 mesylate oral administration healthy male volunteer</brief_summary>
	<brief_title>A Phase I Study IDP-73152 Mesylate Health Male Volunteer</brief_title>
	<detailed_description />
	<criteria>Aged 2050 year inclusive , screen visit . 55kg ≤ Body weight ≤90kg body mass index ( BMI ) 18.0 25.0 kg/m2 . Subject congenital chronic disease without pathologic symptom find medical exam . Subject determine eligible accord result clinical laboratory test like serum test , hematologic test , blood chemistry test , urine test etc . vital sign , electrocardiography , physical exam etc . perform screen exam . Subject decide participate voluntarily give write Informed consent comply instruction listen fully understand detailed explanation trial . Subject clinically significant liver , kidney , neurologic , immunologic , respiratory , endocrine disease hematologic•oncologic disease , cardiovascular disease psychiatric disease ( mood disorder , compulsive disorder etc . ) medical history ( include subject hepatitis virus case liver disease ) . Subject history gastrointestinal disease ( Crohn 's disease , ulcer , acute chronic pancreatitis etc . ) gastrointestinal surgery ( except simple appendectomy hernia operation ) affect absorption study drug . Subject hypersensitivity reaction drug ( aspirin , antibiotic etc . ) history clinically significant hypersensitivity reaction . Specific laboratory value screen include : AST ( SGOT ) and/or ALT &gt; 1.25 time upper limit normal ; QTc &gt; 430 ms clinical significance abnormal electrocardiographic pattern . Uncontrolled hypertension define sustain systolic blood pressure ( SBP ) &lt; 90 mmHg &gt; 150 mmHg diastolic BP ( DBP ) &lt; 60 mmHg &gt; 110 mmHg screen evaluation . History recent tobacco abuse past 3 month . Subject take prescribed drug oriental medicine within 2 week prior first medication overthecounter ( OTC ) drug vitamin within 1 week prior first medication ( however , subject include criterion meet accord discretion investigator ) . Use investigational drug treatment past 2months Subject donate whole blood within 2 month prior first medication apheresis within 1 month prior first medication receive blood transfusion within 1 month prior first medication . Subject continually drink ( excess 21 units/week , 1 unit = 10 g pure alcohol ) abstain drinking study period . History recent tobacco abuse ( within 3 month ) Subject take grapefruit/caffeinecontaining food within 3 day prior first medication , abstain take hospitalization period . Subject judge eligible accord discretion investigator reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>male</keyword>
	<keyword>Phase I</keyword>
	<keyword>A dose block-randomized</keyword>
	<keyword>Double-blinded</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Single Dose</keyword>
	<keyword>dose Escalation</keyword>
	<keyword>IDP-73152 mesylate</keyword>
	<keyword>Food Effect</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>health male volunteer</keyword>
	<keyword>PDF inhibitor</keyword>
</DOC>